Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer

Gong,Jun; Aguirre,Francesca; Hazelett,Dennis; Alvarez,Rocio; Zhou,Lisa; Hendifar,Andrew; Osipov,Arsen; Zaghiyan,Karen; Cho,May; Gangi,Alexandra; Hitchins,Megan

doi:10.3892/mco.2022.2533

Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer

Authors:
- Jun Gong
- Francesca Aguirre
- Dennis Hazelett
- Rocio Alvarez
- Lisa Zhou
- Andrew Hendifar
- Arsen Osipov
- Karen Zaghiyan
- May Cho
- Alexandra Gangi
- Megan Hitchins
View Affiliations

Affiliations: Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA, Department of Biomedical Sciences, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA, Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, CA 92697, USA
Published online on: March 30, 2022 https://doi.org/10.3892/mco.2022.2533
Article Number: 100
Copyright : © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Circulating tumor DNA (ctDNA) is increasingly being investigated as a tool to detect minimal residual disease in resected, stage I‑III colorectal cancer. Recent ctDNA studies have indicated that detection of ctDNA following surgery for resectable colorectal cancer confers a significantly higher risk of recurrence than those with negative ctDNA postoperatively. In those with postoperative ctDNA positivity, clearance of minimal residual disease with adjuvant chemotherapy is a positive prognostic indicator. Lastly, ctDNA has demonstrated superior sensitivity to the conventional blood tumor marker carcinoembryonic antigen (CEA) and can offer median lead times of up to 11 months for radiographic detection of recurrence during the surveillance of resected, stage I‑III colorectal cancer. In metastatic colorectal cancer (mCRC), there is growing evidence to suggest that plasma ctDNA can be used to monitor tumor response to conventional chemotherapy as well. The present case series demonstrated that plasma ctDNA is a predictor of tumor response to immunotherapy in patients with mCRC that are microsatellite stable or microsatellite instability high. Plasma ctDNA could serve as a dynamic marker of immunotherapy response even in colorectal tumors that were CEA non‑producers. Overall, these findings add to ongoing efforts to establish the role of plasma ctDNA in monitoring response to immunotherapy in CRC.

View Figures

View References

1	André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al: Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 383:2207–2218. 2020.PubMed/NCBI View Article : Google Scholar
2	Marcus L, Lemery SJ, Keegan P and Pazdur R: FDA Approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 25:3753–3758. 2019.PubMed/NCBI View Article : Google Scholar
3	Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 18:1182–1191. 2017.PubMed/NCBI View Article : Google Scholar
4	Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al: Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.PubMed/NCBI View Article : Google Scholar
5	Andre T, Berton D, Curigliano G, Ellard S, Pérez JMT, Arkenau HT, Abdeddaim C, Moreno V, Guo W, Im M and Starling N: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. J Clin Oncol. 39 (Suppl 3)(S9)2021.
6	Cho M, Akiba C, Lau C, Smith D, Telatar M, Afkhami M, Sentovich S, Melstrom K and Fakih M: Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases. World J Gastrointest Oncol. 8:128–135. 2016.PubMed/NCBI View Article : Google Scholar
7	Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB III, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, et al: ctDNA applications and integration in colorectal cancer: An NCI colon and rectal-anal task forces whitepaper. Nat Rev Clin Oncol. 17:757–770. 2020.PubMed/NCBI View Article : Google Scholar
8	Hitchins MP, Vogelaar IP, Brennan K, Haraldsdottir S, Zhou N, Martin B, Alvarez R, Yuan X, Kim S, Guindi M, et al: Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. BMJ Open Gastroenterol. 6(e000299)2019.PubMed/NCBI View Article : Google Scholar
9	Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, et al: Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: A proof-of-concept study. Ann Oncol. 28:1996–2001. 2017.PubMed/NCBI View Article : Google Scholar
10	Stein A, Simnica D, Schultheiß C, Scholz R, Tintelnot J, Gökkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, et al: PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. J Immunother Cancer. 9(e002844)2021.PubMed/NCBI View Article : Google Scholar
11	Wang C, Chevalier D, Saluja J, Sandhu J, Lau C and Fakih M: Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer. Oncologist. 25:e1188–e1194. 2020.PubMed/NCBI View Article : Google Scholar
12	Gong J, Hendifar A, Gangi A, Zaghiyan K, Atkins K, Nasseri Y, Murrell Z, Figueiredo JC, Salvy S, Haile R and Hitchins M: Clinical applications of minimal residual disease assessments by tumor-informed and tumor-uninformed circulating tumor DNA in colorectal cancer. Cancers (Basel). 13(4547)2021.PubMed/NCBI View Article : Google Scholar
13	Tie J, Cohen JD, Lo SN, Wang Y, Li L, Christie M, Lee M, Wong R, Kosmider S, Skinner I, et al: Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. Int J Cancer. 148:1014–1026. 2021.PubMed/NCBI View Article : Google Scholar
14	Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, et al: Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5:1124–1131. 2019.PubMed/NCBI View Article : Google Scholar
15	Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, Wong R, Kosmider S, Ananda S, McKendrick J, et al: Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 5:1710–1717. 2019.PubMed/NCBI View Article : Google Scholar
16	Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, et al: Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 8(346ra92)2016.PubMed/NCBI View Article : Google Scholar
17	Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, Tacey M, Wong R, Singh M, Karapetis CS, et al: Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 26:1715–1722. 2015.PubMed/NCBI View Article : Google Scholar
18	Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, et al: Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 30:1804–1812. 2019.PubMed/NCBI View Article : Google Scholar
19	Kotaka M, Shirasu H, Watanabe J, Yamazaki K, Hirata K, Akazawa N, Matsuhashi N, Yokota M, Ikeda M, Kato K, et al: Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clin Oncol. 40 (4 Suppl)(S9)2022.
20	Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtröder K, Gögenur M, Gögenur I, Zimmermann BG, Dyrskjøt L and Andersen CL: IMPROVE Study Group. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA. Mol Oncol. 14:1670–1679. 2020.PubMed/NCBI View Article : Google Scholar
21	Moser T, Waldispuehl-Geigl J, Belic J, Weber S, Zhou Q, Hasenleithner SO, Graf R, Terzic JA, Posch F, Sill H, et al: On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer. NPJ Precis Oncol. 4(30)2020.PubMed/NCBI View Article : Google Scholar
22	Demisse R, Damle N, Kim E, Gong J, Fakih M, Eng C, Oesterich L, McKenny M, Ji J, Liu J, et al: Neoadjuvant immunotherapy-based systemic treatment in MMR-deficient or MSI-high rectal cancer: Case series. J Natl Compr Canc Netw. 18:798–804. 2020.PubMed/NCBI View Article : Google Scholar
23	Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, et al: Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 26:566–576. 2020.PubMed/NCBI View Article : Google Scholar
24	Ma Y, Wang Q, Dong Q, Zhan L and Zhang J: How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 9:1546–1553. 2019.PubMed/NCBI